From the Department of Anatomical Pathology (Tay, Tan), Singapore General Hospital, Singapore.
The Division of Pathology (Tan), Singapore General Hospital, Singapore.
Arch Pathol Lab Med. 2021 Jun 1;145(6):678-686. doi: 10.5858/arpa.2019-0559-RA.
CONTEXT.—: The role of liquid biopsy in cancer management has been gaining increased prominence in the past decade, with well-defined clinical applications now being established in lung cancer. Recently, the US Food and Drug Administration also approved the Therascreen PIK3CA RGQ polymerase chain reaction assay as a companion diagnostic assay to detect PIK3CA mutations in breast cancer for both tissue and liquid biopsies, bringing the role of liquid biopsy in breast cancer management to the fore. Its utility in other aspects of breast cancer, however, is yet to be clearly defined.
OBJECTIVE.—: To review the studies that looked at liquid biopsies in breast cancer and examine their potential for clinical application in the areas of early diagnosis, prognostication, monitoring disease response, detecting minimal residual disease, and predicting risk of progression or relapse. We focus mainly on circulating tumor cells and circulating tumor DNA.
DATA SOURCES.—: Peer-reviewed articles in PubMed.
CONCLUSIONS.—: Liquid biopsies in breast cancers have yielded promising results, especially in the areas of monitoring treatment response and predicting disease progression or relapse. With further study, and hopefully coupled with continued improvements in technologies that isolate tumor-derived materials, liquid biopsies may go on to play a greater role in the breast cancer clinic.
在过去十年中，液体活检在癌症管理中的作用日益凸显，肺癌的明确临床应用已经确立。最近，美国食品和药物管理局还批准了Therascreen PIK3CA RGQ 聚合酶链反应检测，作为一种伴随诊断检测，用于检测乳腺癌组织和液体活检中的 PIK3CA 突变，使液体活检在乳腺癌管理中的作用突显出来。然而，其在乳腺癌其他方面的应用尚待明确。
回顾研究乳腺癌液体活检的相关文献，并探讨其在早期诊断、预后、监测疾病反应、检测微小残留疾病以及预测进展或复发风险等方面的临床应用潜力。我们主要关注循环肿瘤细胞和循环肿瘤 DNA。
PubMed 上的同行评议文章。
乳腺癌液体活检取得了有前景的结果，特别是在监测治疗反应和预测疾病进展或复发方面。随着进一步的研究，希望结合不断改进的分离肿瘤来源物质的技术，液体活检可能会在乳腺癌临床中发挥更大的作用。
